Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Spebrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | ITK | Q08881 | 6/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | TXK | P42681 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | CD69 | Q07108 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spebrutinib SCHEMBL29359972 | 1.00 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518308 | 1.00 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL29722399 | 1.00 | EGFR (1.00) | EGFRBTKITKJAK2LYN | |
| SCHEMBL15814897 | 0.94 | EGFR (0.89) | EGFRBTKITKJAK2LYN | |
| Spebrutinib SCHEMBL17481146 | 0.94 | EGFR (0.89) | EGFRBTKITKJAK2LYN | |
| SCHEMBL12518303 | 0.94 | EGFR (0.88) | EGFRBTKITKJAK2LYN | |
| Spebrutinib SCHEMBL14891298 | 0.92 | EGFR (0.85) | EGFRBTKITKJAK2LYN | |
| SCHEMBL15828854 | 0.92 | EGFR (0.85) | EGFRBTKITKJAK2LYN | |
| SCHEMBL18737405 | 0.91 | EGFR (0.83) | EGFRBTKITKJAK2LYN | |
| SCHEMBL15814036 | 0.91 | EGFR (0.88) | EGFRBTKITKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3394 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-3603672-B1 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | INCYTE CORP (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| EP-4724503-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719403-A1 | METHODS OF TREATING CANCER IN BCL2 INHIBITOR NAIVE SUBJECTS | Curis, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4719407-A1 | METHODS OF TREATING CANCER IN SUBJECTS WITH PRIOR IMMUNE CHECKPOINT INHIBITOR EXPOSURE | Curis, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-20250381181-A1 | CANCER TREATMENT AGENT INCLUDING MALT1 INHIBITING DRUG AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-18 | — | — | US | claimed |
| US-20250361307-A1 | COMBINATION THERAPIES FOR TREATING HYPERPROLIFERATIVE DISORDERS | X4 PHARMACEUTICALS INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-2770830-A1 | METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER | Celgene Avilomics Research, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| WO-2014081714-A2 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2014081712-A2 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2014081709-A2 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20140142129-A1 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | Celgene Avilomics Research, Inc, (US) | 2014-05-22 | — | — | US | claimed |
| US-20140142128-A1 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-05-22 | — | — | US | claimed |
| US-20140140991-A1 | METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-05-22 | — | — | US | claimed |
| WO-2014039452-A1 | METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | WO | claimed |
| US-20130109709-A1 | METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-02 | — | — | US | claimed |
| WO-2013063401-A1 | METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-02 | — | — | WO | claimed |